Please use this identifier to cite or link to this item:
|Title:||Management of side effects of androgen deprivation therapy.|
|Authors:||Grossmann, Mathis;Zajac, Jeffrey D|
|Affiliation:||Department of Medicine Austin Health/Northern Health, University of Melbourne, Heidelberg, Victoria 3084, Australia.|
|Citation:||Endocrinology and Metabolism Clinics of North America; 40(3): 655-71, x|
|Abstract:||Androgen deprivation therapy (ADT) is a major component of the contemporary management of prostate cancer. ADT's use is increasing rapidly. The side effects of this therapy include loss of bone mass and fractures, increase in fat mass, and worsening of insulin resistance, the metabolic syndrome, diabetes and cardiovascular risk, and anemia and loss of muscle. Neuropsychological and sexual symptoms are common. The impact of these side effects is often overlooked or underestimated in decisions about prostate cancer therapy. This review surveys the data relating to the side effects of ADT and provides recommendations regarding their minimization and management.|
|Internal ID Number:||21889727|
|Subjects:||Androgen Antagonists.adverse effects.therapeutic use|
Antineoplastic Agents, Hormonal.adverse effects.therapeutic use
Cardiovascular Physiological Phenomena.drug effects
Drug-Related Side Effects and Adverse Reactions.epidemiology.therapy
Prostatic Neoplasms.drug therapy.epidemiology.metabolism.physiopathology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.